Oncotarget

Research Papers:

NF-kB signaling mediates acquired resistance after PARP inhibition

Yuko Nakagawa _, Anna S Sedukhina, Naoki Okamoto, Satoi Nagasawa, Nao Suzuki, Tomohiko Ohta, Hiroyoshi Hattori, Marta Roche-Molina, Ana J Narváez, Anand D Jeyasekharan, Juan A Bernal and Ko Sato

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:3825-3839. https://doi.org/10.18632/oncotarget.2868

Metrics: PDF 1849 views  |   HTML 2651 views  |   ?  


Abstract

Yuko Nakagawa1,2,*, Anna S. Sedukhina1,*, Naoki Okamoto2, Satoi Nagasawa1,3, Nao Suzuki2, Tomohiko Ohta1, Hiroyoshi Hattori4, Marta Roche-Molina5, Ana J. Narváez6, Anand D. Jeyasekharan7, Juan A. Bernal5, Ko Sato1

1Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki 216–8511, Japan

2Department of Obstetrics and Gynecology, St. Marianna University Graduate School of Medicine, Kawasaki 216–8511, Japan

3Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University Graduate School of Medicine, Kawasaki 216–8511, Japan

4Laboratory of Advanced Therapy, Department of Hematology and Oncology Research, Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya 460–0001, Japan

5Department of Cardiovascular Development and Repair, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid 28029, Spain

6MRC Cancer Unit at the University of Cambridge, Hutchison Research Centre, CB2 0XZ, UK

7Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, 117599, Singapore

*These authors have contributed equally to this work

Correspondence to:

Ko Sato, e-mail: kosato@marianna-u.ac.jp

Received: August 12, 2014     Accepted: December 07, 2014     Published: January 12, 2015

ABSTRACT

PARP inhibitors are a class of promising anti-cancer drugs, with proven activity in BRCA mutant cancers. However, as with other targeted agents, treatment with PARP inhibitors generates acquired resistance within these tumors. The mechanism of this acquired resistance is poorly understood. We established cell lines that are resistant to PARP inhibitor by continuous treatment with the drug, and then used RNA sequencing to compare gene expression. Pathway analysis on the RNA sequencing data indicates that NF-κB signaling is preferentially up-regulated in PARP inhibitor-resistant cells, and that knockdown of core components in NF-κB signaling reverses the sensitivity to PARP inhibitor in resistant cells. Of therapeutic relevance, we show that PARP inhibitor-resistant cells are sensitive to an NF-κB inhibitor in comparison to their parental controls. Malignancies with up-regulation of NF-κB are sensitive to bortezomib, a proteasome inhibitor that is currently used in the clinic. We also show that treatment with bortezomib results in cell death in the PARP inhibitor-resistant cells, but not in parental cells. Therefore we propose that up-regulation of NF-κB signaling is a key mechanism underlying acquired resistance to PARP inhibition, and that NF-κB inhibition, or bortezomib are potentially effective anti-cancer agents after the acquisition of resistance to PARP inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 2868